<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04264936</url>
  </required_header>
  <id_info>
    <org_study_id>RC48-C014</org_study_id>
    <nct_id>NCT04264936</nct_id>
  </id_info>
  <brief_title>A Study of RC48-ADC(Antibody Drug Conjugate) and JS001 to Evaluate the Safety and Pharmacokinetics of Subjects With Locally Advanced or Metastatic Urothelial Cancer</brief_title>
  <official_title>A Open-label, Single-arm, Phase Ib/II Study of RC48-ADC and JS001 to Evaluate the Safety and Pharmacokinetics of Subjects With Locally Advanced or Metastatic Urothelial Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Cancer Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, single-arm, Phase Ib/II investigator-initiated trial of RC48-ADC
      combined with JS001 to evaluate the safety and pharmacokinetics of subjects with locally
      advanced or metastatic urothelial cancer
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">February 15, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 30, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>rate of adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>maximal tolerated dose</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>dose-limiting toxity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peak Plasma Concentration(Cmax)</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Maximum observed plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Numbers of participants with anti-drug antibody positive</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>objective response rate</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first；assessed up to 60 months</time_frame>
    <description>evaluated by RECIST 1.1 every 8 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the area under the curve (AUC)</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Area under the plasma concentration versus time curve</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Urothelial Carcinoma</condition>
  <arm_group>
    <arm_group_label>RC48-ADC and JS001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RC48-ADC and JS001</intervention_name>
    <description>Recombinant Humanized anti-HER2(Human epidermal growth factor receptor-2) Monoclonal Antibody-MMAE(Monomethyl Auristatin E) Conjugate For Injection and JS001 Injection</description>
    <arm_group_label>RC48-ADC and JS001</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent form; Aged 18 years and above; ECOG(Eastern Cooperative
             Oncology Group) performance is 0 or 1; Life expectancy greater than 12 weeks; Patients
             with locally advanced or metastatic malignant urothelial carcinoma which is platinum
             naive and cisplatin ineligible, or progressed after at least one line standard
             systemic chemotherapy (including progression within 12 months of neo-/adjuvant
             therapy);

        Cisplatinum ineligible patients should meet one of the following criteria:

          1. Aged 70 years and above, and ECOG performance is 1;

          2. Serum creatinine &gt;= 1.0xULN or CrCl＜60ml/min;

          3. Lose of hearing &gt;= Grade 2;

          4. Peripheral nerve disorder &gt;= Grade 2 Patients with measurable and appreciable tumor
             lesions according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1);
             Willing to provide primary lesion samples for the purpose of PD-L1 and HER2 tests.

        Adequate organ function as defined by the following criteria:

          1. absolute neutrophil count(ANC) &gt;= 1.5 x 10^9/L;

          2. platelets&gt;=100* 10^9/L;

          3. Total serum creatinine &lt;=1.5*ULN;

          4. serum aspartate transaminase (AST) and serum alanine transaminase (ALT) &lt;=2.5*upper
             limit of normal (ULN), or AST and ALT&lt;=5*ULN if liver function abnormalities are due
             to underlying malignancy; normal serum creatinine ;

          5. Left ventricular ejection fraction (LVEF) ＞=50%

          6. Hemoglobin＞=9g/dl Women of child-bearing potential and men must agree to use adequate
             contraception (e.g., condoms, implants, injectables, combined oral contraceptives,
             some intrauterine devices [IUDs], complete sexual abstinence, or sterilized partner)
             prior to study entry and during the period of therapy and for 30 days after the last
             dose of study drug;

        Exclusion Criteria:

          -  Allergy to RC48-ADC, or JS001, or their components Received anti-cancer therapy
             including chemotherapy, radiotherapy, immunotherapy or other clinical trial treatments
             within 3 weeks of starting study treatment Unresolved toxicities from prior
             anti-cancer therapy, except for alopecia Previously treated with HER2-ADC and/or
             anti-PD-1 or anti-PD-L1 or anti PD-L2 therapies; Underwent major surgery within 4
             weeks of first dose of study drug and not completely recovered; Received vaccine
             within 4 weeks of first dose of study drug Currently active clinically significant
             cardiovascular disease such as uncontrolled arrhythmia, congestive heart failure, or
             greater than or equal to Class 2 congestive heart failure as defined by the New York
             Heart Association Functional Classification, or history of myocardial infarction
             unstable angina, or acute coronary syndrome within 6 months prior to enrollment in the
             study; History of other neoplastic disease within 3 years prior to the study drug,
             with exception of resolved/curable cancers such as basal skin cancer or squamous cell
             skin cancer,.

        Metastasis to CNS(central nervous system) and/or carcinomatous meningitis, with exception
        for the patients who received treatment of metastasis to CNS and/or carcinomatous
        meningitis and had stable disease for at least 3 months, and no evidence of progression
        within 4 weeks of first dose of study treatment. No evidence of new or expanded metastasis,
        and untreated with radiotherapy, surgery or steroid therapy within 4 weeks of first dose of
        study treatment.

        History of allogeneic hematopoietic stem cell transplantation or organ transplantation;
        Patients who had received systemic steroid therapy within the last 2 years; Pregnancy or
        lactation; Positive results of HIV testing; Active HBV(hepatitis B virus) or HCV(hepatitis
        C virus) infection Active tuberculosis; Other disorders with clinical significance
        according to the researcher's judgment; Unwilling or unable to participate in all required
        study evaluations and procedures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>xinan sheng, doctor.</last_name>
    <phone>010-88196348</phone>
    <email>doctor_sheng@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jun Guo, MD</last_name>
      <phone>010-88121122</phone>
      <email>guoj307@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>January 15, 2020</study_first_submitted>
  <study_first_submitted_qc>February 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 11, 2020</study_first_posted>
  <last_update_submitted>February 12, 2020</last_update_submitted>
  <last_update_submitted_qc>February 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Cancer Hospital</investigator_affiliation>
    <investigator_full_name>Jun Guo</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Transitional Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

